Salute e Benessere

New data show Roche's subcutaneously administered crovalimab achieved disease…

The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5 inhibitors 1 Monthly self-administration of subcutaneous crovalimab has the potential to address the high burden of a disease that requires lifelong treatment including in settings where access to current C5 inhibitors is limited 1,2 The COMMODORE 1 study in people switching from currently...
Nasdaq GlobeNewswire
09/06/2023

EdgeCap acquires majority stake in Comac Medical, founder and management retain…

Chris Backes, EdgeCap's co-founder, said: "We are excited to invest in Comac Medical, which over the past 25 years has grown under Milen's leadership into an outstanding business that customers overwhelmingly praise for its quality of service, deep medical expertise in early phase clinical development as well as its speed and agility, specifically with regards to patient recruitment across therapeutic areas and rare indications. We think Comac is uniquely positioned to capitalise on the CRO…
PR Newswire
09/06/2023

Global Photon Counter Market to Surpass USD 3.36 Billion By 2031| Growth Market…

Download PDF Sample here: https://growthmarketreports.com/request-sample/5240 Download PDF Sample here: https://growthmarketreports.com/request-sample/5240 The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, primary materials, applications, and competitor analysis. This report also includes a...
PR Newswire
09/06/2023

Global Multivitamins Supplements to Surpass USD 2.7 Billion By 2031| Growth…

Latest Developments Latest Developments InOctober 2022 , one of the major players in the market Haleon, and Microsoft Corp announced collaboration. The Artificial Intelligence (AI) technology by Microsoft will make health products by Haleon more accessible to blind and visually challenged individuals. With the help of Microsoft Seeing AI app consumers in UK and US will be able to hear information displayed on labels for over 1500 everyday consumer health products. Key Market...
PR Newswire
09/06/2023

Extraordinary General Meeting of Infant Bacterial Therapeutics

At the Extraordinary General Meeting of Infant Bacterial Therapeutics AB (publ) on June 9, 2023, it was resolved to approve the Board of Directors' resolution from May 16, 2023 to increase the company's share capital through the issuance of new shares with pre-emptive rights for the company's shareholders. Subscription may also be made without pre-emptive rights, as set forth in the complete issue resolution.Through the rights issue, IBT's share capital will increase with not more than...
Nasdaq GlobeNewswire
09/06/2023

Chief Executive Officer, Jeff Borcherding, buys Immunovia shares

Immunovia is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Immunovia is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of...
PR Newswire
09/06/2023

Genmab Showcases Data From Comprehensive Epcoritamab Development Program in…

Media ReleaseCOPENHAGEN, Denmark; June 9 , 2023 , at 9:00am CEST Results fromphase 1/2 EPCORE™ NHL-2 trial investigatingepcoritamabin combination with rituximab-lenalidomide (R2) showed a98 percent overall response rate (ORR), 87 percent complete metabolic response (CMR) in patients with relapsed or refractory (R/R) follicular lymphoma (FL)Results from the EPCORE™ NHL-1 expansion cohort, including longer follow-up in...
Nasdaq GlobeNewswire
09/06/2023

DoH and MSD GCC expand partnership during BIO International Convention 2023 to…

Within the framework of their renewed partnership, the two parties will work together to initiate two observational research studies in the field of oncology, explicitly targeting non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). The studies aim to advance the ability to address the healthcare challenges associated with these diseases and improve patient outcomes. Within the framework of their renewed partnership, the two parties will work together to initiate two...
PR Newswire
09/06/2023

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLChas converted 6convertible bonds in Oxurion resulting in a EUR 150 ,000capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.Leuven, BELGIUM ,Boston, MA, US–...
Nasdaq GlobeNewswire
09/06/2023

Nexstim Receives an NBS 5+ System Order from a Customer in the US

Press release, Helsinki, 9 June 2023 at9 AM(EEST) Nexstim Receives an NBS 5+ System Order from a Customer in theUS Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces having received an NBS 5+ system order from the United States. The customer is acquiring the system for neuroscience use.The NBS 5+ system combines the capabilities of Nexstim's NBS (Navigated Brain Stimulation) and NBT® (Navigated Brain Therapy) systems that are both based on Nexstim's...
Nasdaq GlobeNewswire
09/06/2023

China Approves the World's First Vaccine against XBB Descendent Lineages of…

The XBB.1.5 variant had gradually become the major circulating variant in various parts of the world by the beginning of 2023. With the professional guidance and support from the State Council's Joint Prevention and Control Mechanism's vaccine R&D team, the scientific team of WestVac Biopharma/West China Medical Center, Sichuan University overcame all hurdles and successfully developed a vaccine covering XBB family of variants. The XBB.1.5 variant had gradually become the major…
PR Newswire
09/06/2023

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN , Denmark; June 8 , 2023 – Genmab A/S(Nasdaq:GMAB) announced todaythat the Board decided to grant 7,825 restricted stock units and 8,106 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock...
Nasdaq GlobeNewswire
08/06/2023

Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first…

FDA Advisory Committee unanimously recommendsnirsevimab as first immunization against RSV disease forall infantsNirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approvedAcross all clinical trials, a single dose of nirsevimab delivered high, consistent and sustained efficacy and favorable safety against RSV diseaseThe FDA has indicated it will work to expedite its review; Sanofi remains...
Nasdaq GlobeNewswire
08/06/2023

DBV Technologies to Participate in Upcoming EAACI Congress 2023

DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during...
Nasdaq GlobeNewswire
08/06/2023

Voting Rights and Shares Capital of the Company

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, June08, 2023(GLOBE NEWSWIRE) --Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDate Number of SharesOutstanding Total number of voting rightsTotal voting rights,...
Nasdaq GlobeNewswire
08/06/2023

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of…

Company announcement – No. 25 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 8 , 2023 –Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 36,006 divided into 36,006 new shares with a nominal value...
Nasdaq GlobeNewswire
08/06/2023

Sleep Apnea Devices Market worth $8.0 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=719 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=719 Browse in-depth TOC on "Sleep Apnea Devices Market" 316 - Tables 47 - Figures 315 - Pages Sleep Apnea Devices Market Scope: PAP devices segment is expected to account for the largest share in 2022. Positive airway pressure (PAP) devices are the first line of treatment for...
PR Newswire
08/06/2023

New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) ended 2022 on a very strong note, receiving Fast Track Designation (FTD) for its flagship asset, pelareorep, a novel first-in-class intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc.(NASDAQ: ONCY) (TSX: ONC) ended 2022 on a very strong note, receivingFast Track Designation (FTD)for its flagship asset, pelareorep, a novel first-in-class intravenously...
PR Newswire
08/06/2023

Casino Group: press release concerning discussions between TERACT and Casino…

Press release concerning discussions between TERACT and Casino Group Paris, 8 June 2023On March 9, 2023, TERACT and Casino Group entered into exclusive discussions aimed at creating a French leader in responsible and sustainable retail activities, potentially leading to the combination of the two groups' retail activities in France and the establishment of common supply chains closely associating the region's agricultural cooperatives grouped together within the InVivo group, TERACT's...
Nasdaq GlobeNewswire
08/06/2023

Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon…

Regulated Information- Liège, Belgium – 08 June 2023 – 6 PM CET – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) ,a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announced that the Company has been granted EUR 1 million in non-dilutive funding from the Walloon Region for the first part of the development of HY-083.The research into HY-083 aims to offer a treatment option for idiopathic...
Nasdaq GlobeNewswire
08/06/2023

Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos…

Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated Approximately 63% of Cancer Patients in China Experienced a Venous Thromboembolismwithin the First 6 Months of DiagnosisAbelacimab is Already Being Studied in 23 Countries throughout North America, Europe,and Elsewhere in the Asia Pacific Region CAMBRIDGE, Mass., June08, 2023(GLOBE NEWSWIRE) -- Anthos Therapeutics, a...
Nasdaq GlobeNewswire
08/06/2023

LTS completes its entry into large molecule drug delivery with the acquisition…

With the acquisition, Sorrel will become part of the worldwide network of LTS and operate as a new LTS division named LTS Device Technologies. Dr Andrei Yosef has been appointed as President and General Manager of LTS Device Technologies. With the acquisition, Sorrel will become part of the worldwide network of LTS and operate as a new LTS division named LTS Device Technologies. DrAndrei Yosefhas been appointed as President and General Manager of LTS Device Technologies. Bas van...
PR Newswire
08/06/2023

Renal Cell Carcinoma Market to Witness Upsurge in Growth, Assesses DelveInsight…

Key Takeaways from the Renal Cell Carcinoma Market Report Key Takeaways from the Renal Cell Carcinoma Market Report Discover which therapies are expected to grab the major renal cell carcinoma market share @Renal Cell Carcinoma Market Report Renal Cell Carcinoma Overview Renal cell carcinoma, cancerous cells form in the lining of the kidney tubules and expand into a tumour. The growth of this malignancy, like many others, begins modest and develops larger over time...
PR Newswire
08/06/2023

MGI and AddLife AB Announce Strategic Collaboration for Expanded Distribution of…

"At AddLife, we aim to meet all our customers' needs at the highest level. Innovation is one of our core values and the addition of the product line from MGI is a perfect complement to our laboratory portfolio in that respect. It gives our customers the possibility to use the most modern and innovative technology." Kai Rantanen, Head of the Diagnostic Business at AddLife AB said. "At AddLife, we aim to meet all our customers' needs at the highest level. Innovation is one of our…
PR Newswire
08/06/2023
Altri  Comunicati